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Abstract Dynamic preservation strategies such as hypother-
mic machine perfusion are increasingly discussed to improve
liver graft quality before transplantation. This review summa-
rizes current knowledge of this perfusion technique for liver
preservation. We discuss optimization of perfusion conditions
and current strategies to assess graft quality during cold per-
fusion. Next, we provide an overview of possible pathways of
protection from ischemia-reperfusion injury. Finally, we re-
port on recent clinical applications of human hypothermic
machine liver perfusion.
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Abbreviations
CS cold storage
NMP normothermic machine perfusion
SNMP subnormothermic machine perfusion
HMP hypothermic machine perfusion
DCD donation after cardiac death
ROS reactive oxygen species
DAMPs danger-associated molecular patterns
UW University of Wisconsin
MP machine perfusion





BCL-2 protein B cell lymphoma 2 protein
BH-3 Bcl-2 homology-3
BID BH-3-interacting domain
BAX Bcl-2-associated x protein
BAK Bcl-2-antagonist/killer-1
MPT Pore mitochondria permeability
transition pore
IAP binding protein inhibitor of apoptosis protein




DISC death-inducing signaling complex
miRNA micro-RNA
ER endoplasmic reticulum
HMGB-1 high-mobility group box protein 1
RAGE receptor for advanced glycation
end products
TLR-4 roll-like receptor 4
LPS lipopolysaccharides
ATP adenosine triphosphate
HOPE hypothermic oxygenated perfusion
DBD donation after brain death
Introduction
Nearly one century ago, Alexis Carrel and Charles Lindbergh
developed the first device for automatic ex vivo perfusion of
small organs at body temperature with an oxygenated solution
[1]. Remarkably, despite numerous technical advances since
that time, no system has been able to maintain complete func-
tion of organs (livers, kidney, lungs or hearts) for more than
several days outside of the body [2, 3]. In contrast, because of
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the simplicity and effectiveness, preservation of solid organs
for transplantation has been predominantly performed by cold
storage (CS) at 4 °C for the last 4 decades [4–6]. Over the past
10 years, however, the development of novel dynamic preser-
vation techniques to improve organ quality before implanta-
tion has received increasing attention. For the liver, the main
debate over machine perfusion relates to three separate ap-
proaches, differing in perfusate temperature and the degree
of oxygenation: normothermic, subnormothermic and hypo-
thermic liver perfusion. While normothermic machine perfu-
sion (NMP) closely simulates in vivo conditions and therefore
needs oxygenated diluted blood and nutritional compounds as
perfusate [7–9], subnormothermic machine perfusion
(SNMP) and hypothermic machine perfusion (HMP) rely
on the physically dissolved oxygen in a blood-free perfusate
at temperatures of 20-25 °C (subnormothermic) [10, 11] or
2-10 ° (hypothermic) [12, 13].
For the purpose of this review, we will focus on the follow-
ing aspects of the current research on HMP: key questions on
perfusion conditions, new insights into assessing graft func-
tion during HMP, and the underlying mechanisms of protec-
tion and associated clinical applications.
Perfusion Conditions
HMP techniques for liver preservation vary significantly in
experimental setups. The most common variations relate to
the degree of oxygenation, the perfusion route and flow, and
the perfusate composition (Tables 1 and 2) [14].
Is Active Oxygenation Necessary?
Oxygen consumption of liver tissue decreases with decreasing
temperature, but does not completely stop under CS (4 °C)
[21]. Reported perfusate oxygenation during liver HMP stud-
ies ranges between 10 and 100 kPa (Tables 1 and 2), yet the
optimal level of oxygenation remains unclear. Dissolved oxy-
gen may be sufficient at 4 °C for standard livers donated after
brain death (DBD) [16]. Previous studies, however, confirm
that livers exposed to warm ischemia before organ procure-
ment, for example, donation after cardiac death (DCD) do-
nors, have higher oxygen demands than controls [12]. It has
also been shown that active oxygenation, compared to no
oxygenation, is protective for DCD livers [17].
Some studies have reported oxidative stress when isolated
hepatocytes are exposed to oxygen under cold conditions.
This stress is due to the reaction of oxygen with increased
intracellular redox-active iron ions, which triggers free
radical-mediated cell injury [18]. Based on this, researchers
have been reluctant to combine cold liver perfusion with ox-
ygenation. In contrast to these reports, however, a significant
number of oxygenated perfusion experiments in livers [15, 17,
19–21] and kidneys [22] have demonstrated only minimal
oxidative stress during hypothermic oxygenated perfusion de-
spite high oxygen concentrations.
Importantly, the rate of oxygen consumption during
HMP decreases rapidly during the first hour and ceases
after 90 min at a low baseline level because of down-
regulation of mitochondrial respiration despite increasing
ADP and sufficient levels of substrates (oxygen and
electron donors) [15, 23, 24]. Accordingly, during hypo-
thermic oxygenated liver perfusion, mitochondria switch
from a high-flux electron transfer stage at the beginning
of machine perfusion to a low-flux electron transfer
stage during approximately 60-90 min of perfusion.
Conversely, in the complete absence of oxygen, mito-
chondria stay in a reduced high flux state and trigger
high release of mitochondrial-derived reactive oxygen
species (ROS) during the first minutes of reperfusion
[25••). This in turn leads to the release of nuclear
danger-associated molecular patterns (DAMPs) and sub-
sequent downstream activation of nonparenchymal liver
cells [15, 25••]. Therefore, protection of liver grafts
against significant oxidative stress depends on sufficient
mitochondrial oxygenation during hypothermic perfusion
of livers before exposure to blood and oxygen at nor-
mothermic conditions.
Is low Perfusion Pressure Sufficient?
Another aspect of the debate regarding HMP relates to the
determination of the optimal perfusion pressure necessary
for cold machine liver perfusion (Tables 1 and 2). Because
liver sinusoids are known to be very sensitive to endothelial
shear stress, a balance is needed between the perfusion of a
maximum of liver cells and minimal endothelial injury. Previ-
ous work in rat livers suggests that the reduction of portal
perfusion pressure to 4 mmHg achieves both complete perfu-
sion and no endothelial injury, while perfusion at 8 mmHg
induced endothelial injury [15, 26]. Recent studies by our
group in animal models and human livers confirm that a low
portal perfusion pressure of 3 mmHg results in complete per-
fusion without evidence of sinusoidal impairment [15, 27••].
In contrast, hypothermic portal perfusion at higher pressures
results in clear deterioration of endothelial cells [15]. Based on
this, a significant reduction of the portal perfusion pressure to
≤3 mmHg appears to have a decisive and positive effect dur-
ing cold oxygenated liver perfusion and minimizes the risk of
endothelial shear stress.
Is Portal Perfusion Alone Adequate in Hypothermic
Conditions?
The best perfusion route during HMP has been discussed
widely. Some researchers argue that simultaneous delivery
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of the perfusate and oxygen through the portal vein and the
hepatic artery would increase the benefit of HMP [28]. Due to
the fact that portal and arterial branches join in the liver sinu-
soids, single portal perfusion allows for circulation to all he-
patocytes in less than 1 min after the start of low-pressure cold
perfusion in a pig model (Fig. 1). Considering the low oxygen
demand of livers under cold temperatures, the supply of oxy-
gen by single-portal perfusion appears sufficient, at least for
hepatocytes, endothelial cells, Kupffer cells and intrahepatic
interlobular biliary branches. Consistently, HMP in discarded
human livers showed no difference in perfusion quality be-
tween singular perfusion of the portal vein or the hepatic ar-
tery alone versus dual perfusion [29]. Whether additional ar-
terial hypothermic perfusion is useful for the viability of the
extrahepatic bile ducts remains to be investigated. Recent
studies suggest that most biliary injury is triggered through a
cascade of mediators released during early reperfusion rather
than by ischemia itself [21].
Is the Perfusion Medium Important?
The perfusates used during liver HMP in the majority of ex-
periments are based on the original or modified UW (Univer-
sity of Wisconsin) solution or UW machine perfusion (MP)
solution. Perfusion studies with IGL (Institut George Lopez),
Celsior or HTK (Histidine-Tryptophan-Ketoglutarate) solu-
tions have been performed (Tables 1 and 2); however, no
conclusive comparison of machine liver perfusates is avail-
able. As low potassium concentrations decrease vascular re-
sistance in hypothermia, the presence of starch increases vis-
cosity. Therefore, solutions with low potassium and without
starch appear advantageous [30], but an ideal perfusate for
liver HMP has yet to be determined. Besides the fundamental
implication of oxygen in the cold perfusate, additional
Bcleaning^ effects on the sinusoidal glycocalyx are also im-
portant during liver HMP [15].
Hypothermic machine perfusion and subsequent transplan-
tation of human livers were performed using CE-certified UW
gluconate (KPS-1®, Belzer UWMP®) or with a modification
of UW gluconate including α-ketoglutarate, L-arginine, N-
acetylcysteine and prostaglandin E1 [16].
Is end-Ischemic Perfusion Effective?
End-ischemic perfusion is initiated after CS and transport of
organs to the transplant center. Because transport of perfusion
devices to the place of procurement is not needed, this concept
is very practical and easy. In addition, recent research in rat,
pig and human livers shows that despite a relatively long CS
period of up to 8 h, end-ischemic hypothermic oxygenated
perfusion protects liver grafts [12, 13, 15, 27••, 31, 32]. This
effect is the result of significant uploading of liver energy
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mitochondrial electron carriers from a reduced to oxidized
stage [15]. Similar results have been reported by end-
ischemic gaseous oxygen persufflation of livers and kidneys
under hypothermic conditions [33, 34].
Assessment of Liver Injury During HypothermicMachine
Liver Perfusion
While several studies have analyzed organ injury during NMP
[35–37], less is known about the behavior of liver grafts
during HMP. Measurement of hepatocellular and mitochon-
drial injury during HMP provides useful information for graft
assessment, but important questions remain and need to be
addressed. Here we report on the current findings.
Markers of Hepatocellular Injury
Release of cytosolic hepatocyte enzymes, such as AST, ALT
and LDH, is simple and can be measured in cold perfusates
during liver HMP. Importantly, and as related to graft assess-
ment, ALT release per gram of liver during HMP correlates
Fig. 1 Perfusion flow at low
pressure (3 mmHg) appears
comparable for different species
(rat, pig, human), if related to liver
weight (A, B). Oxygen
consumption during hypothermic
machine liver perfusion decreases
during the first hour of perfusion
and stays at a low level during
further perfusion (C).
Angiography during low-pressure
hypothermic perfusion of pig
DCD livers demonstrates
complete perfusion of all
sinusoids within the first minutes
by exclusively portal vein
perfusion (D)
Table 2 In vivo studies on hypothermic machine liver perfusion
Author Year Species Oxygenation Pressure Route Medium Duration (h)
Continuous perfusion
Pienaar [3] 1990 Dog na 16–18 mmHg PV UW 72
Uchiyama [84] 2001 Pig na HA: 30-60 mmHg HA+PV UW-MPS 2
Iwamoto [85] 2000 Pig na PV:8 mmHg, HA 20-80 mmHg HA+PV na 2
Lee [13] 2003 Rat na na PV UW 5
Vekemans [86] 2009 Pig 310 mmHg na na 3 different
(KPS, Aqix-Rs1)
4
Monbaliu [87] 2011 Pig no active oxygenation PV 7 mmHg, HA 30 mmHg HA+PV KPS-1 4
Fondevila [88] 2012 Pig HA: 90kPa PV and HA
(4 mmHg PV, 20-30 mmHg HA)
HA+PV UW MP 4
Endischemic perfusion
de Rougemont [31] 2009 Pig >60 kPa 3 mmHg PV UW modified 1
Schlegel [21] 2013 Rat 90 kPa, 750 mmHg 3 mmHg PV UW modified 1
Schlegel [49•] 2014 Rat 90 kPa, 750 mmHg 3 mmHg PV UW modified 1
Schlegel [50] 2014 Rat 90 kPa, 750 mmHg 3 mmHg PV UW modified 1
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with the release of ALT during reperfusion injury after trans-
plantation [16]. Furthermore, effluent analysis during HMP
allows the determination of several acute phase reactants [38].
The soluble fraction of cytokeratin-18 (CK18), the major
filament protein in the liver, has been shown to be released
into the extracellular space during liver cell death. As full-
length CK19 is cleaved by caspases during apoptotic cell
death, CK18 fragments are believed to present a means for
monitoring epithelial apoptotic liver cell death [39•).Measure-
ment of CK18 fragments is feasible during HMP, but future
research is needed to introduce these new tests for use in
regular graft assessment.
Small non-coding RNAs (21-25 nucleotides), known as
microRNA (miRNA), play an important role in the regulation
of gene expression. These RNAs are generated and exported
from the nucleus. The most abundant liver-specific miRNA is
miR-122, which is released into the circulation during hepa-
tocyte damage [40] and is therefore detectable during HMP.
Furthermore, increased miR-222 may display cholangiocyte
damage and was suggested to predict cholangiopathy after
liver transplantation [39•, 41, 42].
Markers of Mitochondrial Injury
Mitochondrial dysfunction causes either massive destruction
of hepatocytes or sensitization of liver cells to a variety of
otherwise non-lethal stress conditions. Executioner caspases
and mitochondrial outer membrane permeabilization are crit-
ical for the death of hepatocytes, triggered by mitochondria
[43]. The mechanisms of such mitochondria-derived injury
are at least threefold:
1. Intracellular signaling: Several intracellular stress condi-
tions are sensed by small members of the BCL-2 protein
family (BH3-only proteins), which can activate mitochon-
drial outer membrane permeabilization by stimulating the
pore-forming activity of BAX and BAK [43, 44].
2. Intramitochondrial signaling: outer membrane perme-
abilization can also be initiated at the inner mitochondrial
membrane by an unspecific opening of the mitochondrial
permeability transition pore complex (MPT-pore),
resulting in the release of mitochondrial ROS and pro-
teins, such as cytochrome C, direct inhibitor of
apoptosis-binding protein with low pI (DIABLO) and
apoptosis-inducing factor (AIF) [43, 45].
3. Extracellular signaling: death receptors of the tumor ne-
crosis factor family (Fas) are activated by extracellular
signals from the Fas ligands at the cell surface. Upon
binding, these receptors form the intracellular death-
inducing signaling complex (DISC) and trigger either
cleavage of initiator caspase 8 or activation of pro-
apoptotic proteins (Bid, Bax), resulting in the assembly
of the apoptosome complex (cytochrome c, Apaf-1,
caspase 9) and activation of caspase 3 [44].
Currently, there is no experience in differentiating the dis-
tinct signaling pathways of mitochondrial injury during HMP.
However, future research may allow selective determination
of liver epithelial injury, mitochondrial or nuclear-derived in-
jury by measuring CK18 fragments, special miRNAs, mito-
chondrial membrane proteins (cytochrome c) or apoptosis-
related proteins (SMAC, DIABLO) during cold machine liver
perfusion.
Ischemia Reperfusion Injury of Liver Grafts
Mitochondrial Injury is a key Event
Efforts to restore blood flow in hypoxic tissue can paradoxi-
cally result in more destructive than beneficial effects, depend-
ing on the length of the ischemic period. Previous research
indicates that the main damaging effects in ischemic reperfu-
sion (I/R) injury involve reactions following restoration of
blood flow to the tissue rather than the ischemia itself [25••).
Under conditions of oxygen deficiency, oxygen molecules in
the mitochondrial respiratory chain accept only one electron
instead of four as accepted under normal conditions, therefore
producing mitochondrial ROS (Fig. 2). The generation of
ROS by mitochondria in turn triggers the MPT opening and
subsequent nuclear damage and endoplasmic reticulum (ER)
stress responses [25••]. Danger-associated molecular patterns
(DAMPs) that are released by dying hepatocytes play a major
role in this context [15, 46].
DAMPs: Signals for Inflammation and Cell Death
DAMPs are a group of molecules that are exposed by dying
cells to operate as modulators of sterile inflammation. By
binding to specific pattern-recognition receptors, DAMPs ex-
ert immune-modulatory functions with a wide panel of proin-
flammatory factors. The high-mobility group box-1 (HMGB-
1) protein is a highly conserved, abundant, non-histone nucle-
ar protein expressed in almost all eukaryotic cells. Cellular
effects of HMGB-1 are induced through signal pathway re-
ceptors, such as the receptor for advanced glycan end products
(RAGE) and Toll-like receptor 4 (TLR4) [47]. Within the
nucleus, HMGB-1 modulates and facilitates the transcription
of many genes. Once released from cells, HMGB-1 acts as a
component of the innate immune system alerting the host-to-
cell stress (Fig. 3). HMGB-1 is hyperacetylated upon activa-
tion with LPS in monocytes and macrophages, while
unacetylated HMGB-1 is thought to be released by necrotic
cells. Further hepatotoxic effects originate from a downstream
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crosstalk among hepatocytes, tissue-resident immune cells
(macrophages) and immune cells that are recruited to the site
of injury [47].
Mechanism of Protection by Hypothermic Oxygenated
Perfusion
Attenuation of Oxidative Phosphorylation Pathway
An important and unexplained finding of hypothermic oxygen-
ated liver perfusion is the discovery that it is possible to upload
depleted cellular energy stores within a short perfusion time,
even after significant warm and cold ischemia. While the exact
mechanism of this phenomenon remains unclear, the low ener-
gy demand in hypothermic conditions and the continuous
supply of oxygen favor a positive ATP balance, despite a rapid
decrease in the mitochondrial respiration rate [15, 17, 48]
(Fig. 2). Of note, hypothermic oxygenated liver perfusion is
more effective in this respect as compared to normothermic
oxygenated perfusion [49•].
Inhibition of Mitochondria-Derived ROS and Downstream
Mediators
Hypothermic oxygenated machine perfusion changes the mi-
tochondrial redox state by reversible suppression of oxidative
metabolism, and subsequently decreases the initial ROS re-
lease during normothermic reperfusion [15]. Consequently,
less mitochondrial injury triggers less release of mitochondrial
ROS and therefore less nuclear injury via several pathways
and results in less release of DAMPs into the circulation [46,
Fig. 2 Physiological release of
reactive oxygen species (ROS)
occurs in mitochondria between
complex II and III. During
ischemia reperfusion, however,
this ROS release increases
significantly and can initiate






AIF) are released in the cytosol,
which activate different cell
organelles. Hypothermic
oxygenated perfusion prevents
the initial mitochondrial ROS
release
Fig. 3 ROS release from
mitochondria leads to nuclear
injury and release of danger-
associated molecular patterns
(DAMPs) (A), which in turn
stimulate Kupffer cells via Toll-
like receptors once released by
hepatocytes (B). Activated
Kupffer cells release mediators
and intravasal ROS (C), which
activate downstream endothelial
cells and platelets (D)
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49•] (Fig. 3). In turn, Kupffer cell activation is decreased by
hypothermic oxygenated perfusion with a smaller release of
secondary mediators and less activation of neutrophils and
platelets [25••, 49•] (Fig. 3). The effect of these reactions on
the immune response (T cell activation) and biliary epithelial
cells has been recently reported [21, 50].
Clinical Application of Hypothermic Liver Perfusion
The group at Columbia University in New York first perfused
ten discarded human livers for 7 h through the portal vein and
hepatic artery without active perfusate oxygenation, using me-
dian high flow rates of 0.7 ml/g liver /min. Liver quality was
assessed by AST release in the perfusate [51]. In a subsequent
clinical study, machine-perfused livers were implanted in 20
patients, with suggested improvement in early graft function,
lower serum transaminase levels and shorter hospital stay com-
pared to a historical group of cold-stored standard liver grafts
donated after brain death (DBD). The study follow-up was
limited to 3 months. Of importance, while the perfusate was
not actively oxygenated, measurements of pO2 levels in the
perfusate confirmed no change in perfusate oxygen concentra-
tions during the entire HMP period [16], probably because of
the high perfusion flow under hypothermic conditions.
Meanwhile, this group reported on 40 machine-perfused
human liver grafts from DBD donors and demonstrated re-
duced activation of adhesions molecules as well as less acti-
vation of leukocytes in cold-perfused livers compared to cold-
stored controls [52].
Two other groups [Royal Free Hospital, London [29] and
KU Leuven [53] perfused discarded human livers for up to
24 h with an assessment of liver viability by liver enzyme
release and morphology during cold perfusion. In one addi-
tional study, Vekemans et al. randomly allocated 27 discarded
human livers to cold storage or hypothermic perfusion for 4 h
(total preservation time of 15-17 h). The degree of reperfusion
injury was detected during ex vivo reperfusion of all liver
grafts at normal body temperature with diluted red blood cells
for 2 h, only showing reduced AST and LDH release in the
perfusion group as compared to cold-stored livers, but no
morphological difference could be identified [54].
Over the last decade, another technique of HMP was devel-
oped from our group, delivering a hyperbaric oxygenated per-
fusate (>50 kPa pO2) through the portal vein at low pressure
(<3 mmHg) for 1-2 h after a certain period of CS immediately
prior to graft implantation. This perfusion technique has been
tested in human DCD liver grafts [27••]. The application of this
perfusion method, termed hypothermic oxygenated perfusion
(HOPE), was the result of 15 years of experimental work in
numerous animal models, which have shown strong protective
effects, despite its short application through the portal vein only
[12, 15, 19, 21, 31, 49•, 50, 55–57]. The rationale for applying
such machine perfusion in DCD liver grafts was based on na-
tional ethical specifications that have prevented the procure-
ment of grafts with less than 10 min warm ischemia after dec-
laration of cardiac death (asystolic warm ischemia <10 min). In
its inaugural clinical application, HOPEwas applied consistent-
ly to eight extended human DCD liver grafts with prolonged
asystolic warm ischemia periods up to 20 min (asystolic time)
and increased donor age (median 54 years), a figure that would
prevent the use of liver grafts in most centers [58, 59]. In this
first human series, involving a 6-month follow-up after HOPE
in DCD livers, no intrahepatic cholangiopathies were detected.
Of note, and in contrast to all other perfusion strategies that
need to be started at the site of procurement and require con-
tinuous pumping, this novel perfusion setting is highly simpli-
fied and low cost. Our center applied the HOPE technique in 25
human DCD livers with excellent and immediate graft function
in all cases and no evidence of intrahepatic biliary injury in
spite of long donor warm ischemia.
Conclusions
HMP can protect liver grafts exposed to warm and cold ische-
mia. This effect is probably linked closely to changes in mi-
tochondrial electron transfer rates during cold machine perfu-
sion and therefore depends on the abundance of oxygen dur-
ing perfusion. Short-term (1-2 h) perfusion appears as effec-
tive as longer perfusion (10 h). Application of end-ischemic
hypothermic oxygenated perfusion in human DCD livers was
well tolerated in recent transplant series. Randomized trials are
needed to further assess the full protective action of liver
HMP, in particular with respect to biliary complications after
liver transplantation.
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